newsfilter
← Latest News
GlobeNewswire·

Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021 -- Company Reiterates Full Year 2022 Financial Guidance BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE)